Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,586 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo:0.9% sodium chloride Clear all
Completed Phase 2 Interventional Results available

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01408030
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions
Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
Drug
Lead sponsor
James Gossage
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

FEIBA and Use of Blood Products in Cardiac Surgery

NCT02577614
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
FEIBA, Normal Saline
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 17, 2026, 8:14 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

NCT06967181
View directory record Official record
Conditions
Mumps
Interventions
CVM150, CVM26, Placebo
Biological · Other
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 29 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy

NCT03875664
View directory record Official record
Conditions
Postoperative Pain
Interventions
Liposomal bupivacaine, Placebo - injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132
View directory record Official record
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients

NCT02152163
View directory record Official record
Conditions
Pain
Interventions
IV Ibuprofen, placebo
Drug
Lead sponsor
Delray Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Early Phase 1 Interventional

Angiotensin 1-7 in Obesity Hypertension

NCT03604289
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Amy Arnold
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

NCT02661490
View directory record Official record
Conditions
Norovirus
Interventions
Norovirus GI.1/GII.4 Bivalent VLP Vaccine, 0.9% sodium chloride (saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

NCT03738475
View directory record Official record
Conditions
Celiac Disease
Interventions
TIMP-GLIA, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Jacksonville, Florida • Meridian, Idaho • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 17, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness

NCT06600581
View directory record Official record
Conditions
Muscle Performance, Sarcopenic Obesity
Interventions
IMM01-STEM, Placebo, IMM01-STEM alternating with placebo (saline)
Biological · Other
Lead sponsor
Immunis, Inc.
Industry
Eligibility
60 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Garden Grove, California • Pomona, California • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

NCT00306137
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

NCT04995081
View directory record Official record
Conditions
Parkinson Disease
Interventions
Biological/Vaccine: Allogeneic HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery

NCT00041392
View directory record Official record
Conditions
Coronary Disease, Heart Diseases, Cardiovascular Diseases, Neurologic Manifestations
Interventions
Magnesium, 0.9% saline
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

NCT00348439
View directory record Official record
Conditions
Vitreoretinal Traction Syndrome
Interventions
Plasmin, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

NCT04348500
View directory record Official record
Conditions
COVID-19
Interventions
Clazakizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

NCT04344600
View directory record Official record
Conditions
Sars-CoV-2 Infection
Interventions
Peginterferon lambda alfa-1a subcutaneous injection, Saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Results available

The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia

NCT01146457
View directory record Official record
Conditions
Labor Pain
Interventions
Morphine, Saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

NCT03984812
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3732394, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 17, 2026, 8:14 PM EDT
Withdrawn Phase 2 Interventional

Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

NCT07196306
View directory record Official record
Conditions
COVID, COVID-19, Corona Virus Infection
Interventions
Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
BayCare Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Clearwater, Florida • St. Petersburg, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 17, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
North Hollywood, California • San Diego, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

NCT00850993
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Stannsoporfin, Placebo, PhotoTherapy (as needed)
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Minute to 48 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 17, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mouth Rinses for Inactivation of COVID-19

NCT04584684
View directory record Official record
Conditions
Covid19, Coronavirus Infection, SARS-CoV-2 Infection
Interventions
0.9% w/v NaCL Saline, 1.5% w/v Hydrogen Peroxide, 0.12% Chlorohexidine Gluconate, 27% Ethanol plus essential oils, 0.5% w/v Povidone-iodide, 0.075% Cetylpyridinium Chloride
Other · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 17, 2026, 8:14 PM EDT